Biotech Values

[DewDiligence]

BMY releases additional Opdivo/chemo and Opdivo/Yervoy data from the CHECKMATE-648 study in certain GI cancers:

https://www.businesswire.com/news/home/20210603005918/en

In Apr 2021, BMY announced that this study hit its OS primary endpoint for both the Opdivo/chemo and Opdivo/Yervoy arms, compared to chemo alone (#msg-163050617), but no details were available until now.

The dataset is complex and you need a scorecard to understand all of it; fortunately, Evaluate Vantage has provided one:

https://www.evaluate.com/vantage/articles/events/conferences/asco-2021-bristol-makes-more-progress-stomach-cancer

Note: Opdivo/chemo is already FDA-approved in a different kind of metastatic GI cancer, based on the CHECKMATE-649 (rather than -648) study (#msg-163247972); and Opdivo monotherapy is already FDA-approved in adjuvant esophageal cancer, based on the CHECKMATE-577 study (#msg-163936079).